Calcium levels decreased less with each subsequent denosumab dose among individuals with osteoporosis and advanced chronic kidney disease.

Renal gluconeogenesis ... 17.8 PPG (mg/dl):/DP20 mg: −41.9/DP10 mg: −34.3/PL: 18.7 Body weight (kg):/DP20 mg: −4.3/DP10 mg: −4.5/PL: −1.9 Urinary glucose excretion (g/24 h):/DP20 ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

Janux Therapeutics (NASDAQ:JANX – Get Free Report)‘s stock had its “outperform” rating reissued by equities research analysts at William Blair in a research report issued to clients and investors on ...

also may reduce inflammation and slow the decline in glomerular filtration rate (GFR) in patients during the earlier stages of CKD. Conclusion: Because of the high rate of CVD in patients with CKD ...

"Notably, the FDA also confirmed that ProKidney could consider using eGFR slope as a surrogate endpoint on an accelerated ... and address the high unmet need in patients with advanced CKD and diabetes ...

Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

Findings from Spherix Global Insights show that practitioners consider nearly half of their C3G patients to be potential candidates for Fabhalta or Empaveli, if approved.EXTON, PA, Nov. 15, 2024 ...

Ketoanalogue supplements can enable patients to continue to meet their protein needs without exacerbating nitrogen load.